Danaher Corporation vs Paychex, Inc. — how do they compare? Danaher Corporation trades at $219.87 (market cap $152.87B), while Paychex, Inc. trades at $103.98 (market cap $37.19B). The key difference: Danaher Corporation is far larger — about 4.1× Paychex, Inc.'s market cap, and Paychex, Inc. pays the higher dividend (4.56%). Which is the better fit depends on your goals — on Pluang, investors hold Danaher Corporation for 69 Days and Paychex, Inc. for 56 Days on average.
| DHR | PAYX | |
|---|---|---|
Market Cap | $152.87B | $37.19B |
Volume | 5,228,698 | 3,344,316 |
Sector | Health | Industrials |
52-Week High | $242.05 | $128.59 |
52-Week Low | $161.91 | $85.57 |
Typical Hold Time | 69 Days | 56 Days |
Enterprise Value | $175.08B | $40.87B |
Dividend Yield | 0.74% | 4.56% |
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $217.46, down 0.47% on the day, with a bullish technical signal from moving averages and support at $214. The company shows strong profitability with a 58.51% gross margin and has beaten EPS estimates for three consecutive quarters. Recent news includes a declared $0.40 dividend payable in October 2026 and significant institutional buying, such as Bank of America's new $993.8 million stake in Q2 2026.
The outlook is positive with a consensus price target of $230.31, implying 5.9% upside, supported by 70% analyst buy ratings. Risks include elevated valuation multiples like a P/E of 38.76 and fluctuating cash flows, but earnings growth in biotechnology and steady revenue provide a solid foundation for investor confidence.
Paychex (PAYX) trades at $104.46, up 2.87% on the day, with a mixed technical outlook showing a bullish overall signal but bearish moving averages. The company continues to deliver strong fundamentals, beating earnings estimates for the last three quarters with a net income margin of 27.35% and robust ROE of 47.06%. Recent news highlights earnings beats but also concerns over stock performance and dividend sustainability despite a recent 5-star rating from Newsweek.
The stock presents a cautious opportunity with a consensus price target of $111 offering ~6% upside, but risks include a high P/E of 20.73, significant debt increase, and sensitivity to labor market trends. Investor sentiment is divided, with analyst consensus leaning Hold, reflecting balanced growth prospects against valuation and macroeconomic headwinds.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →Paychex is a leading provider of payroll, human capital management, and insurance solutions servicing small and midsize clients primarily in the United States. The company, established in 1979, services over 730,000 clients and pays over 1 in 12 U.S. private-sector workers. Alongside its traditional payroll services, Paychex offers HCM solutions such as benefits administration and time and attendance software, as well as human resources outsourcing and insurance agency services.
Read more on PAYX →